These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11673814)

  • 21. Randomized salvage therapy with saquinavir-ritonavir versus saquinavir-nelfinavir for highly protease inhibitor-experienced HIV-infected patients.
    Chavanet P; Piroth L; Grappin M; Buisson M; Gourdon F; Cabié A; Duong M; Brunel-Dalmas F; Peytavin G; Portier H
    HIV Clin Trials; 2001; 2(5):408-12. PubMed ID: 11673815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.
    Rizzardi GP; Tambussi G; Bart PA; Chapuis AG; Lazzarin A; Pantaleo G
    AIDS; 2000 Oct; 14(15):2257-63. PubMed ID: 11089613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical efficacy of protease inhibitor based antiretroviral combination therapy--a prospective cohort study.
    Salzberger B; Rockstroh J; Wieland U; Franzen C; Schwenk A; Jütte A; Hegener P; Cornely O; Mörchen C; Gaensicke T; Diehl V; Fätkenheuer G
    Eur J Med Res; 1999 Nov; 4(11):449-55. PubMed ID: 10585299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
    Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine.
    Mocroft A; Devereux H; Kinloch-de-Loes S; Wilson D; Madge S; Youle M; Tyrer M; Loveday C; Phillips AN; Johnson MA
    AIDS; 2000 Jul; 14(11):1545-52. PubMed ID: 10983641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.
    Chêne G; Binquet C; Moreau JF; Neau D; Pellegrin I; Malvy D; Ceccaldi J; Lacoste D; Dabis F
    AIDS; 1998 Dec; 12(17):2313-20. PubMed ID: 9863874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of indinavir and higher CD4+ T-cell count on viral load response after 6 months of highly active antiretroviral therapy.
    Pradier C; Pesce A; Carrieri P; Cottalorda J; Boyer P; Senesi C; Fuzibet JG; Dellamonica P; Cassuto JP
    Clin Ther; 1999 Aug; 21(8):1313-20. PubMed ID: 10485503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
    Mallolas J; Blanco J; Labarga P; Vergara A; Ocampo A; Sarasa M; Arnedo M; López-Púa Y; García J; Juega J; Guelar A; Terrón A; Dalmau D; García I; Zárraga M; Martínez E; Carné X; Pumarola T; Escayola R; Gatell J
    HIV Med; 2007 May; 8(4):226-33. PubMed ID: 17461850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.
    Figgitt DP; Plosker GL
    Drugs; 2000 Aug; 60(2):481-516. PubMed ID: 10983742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
    Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
    JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
    HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
    Gray CM; Schapiro JM; Winters MA; Merigan TC
    AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Saquinavir hard gel suppresses viral load insufficiently in HIV-infected patients naive to anti-retroviral therapy: a retrospective cohort study.
    Jensen-Fangel S; Kirk O; Larsen L; Blaxhult A; Gerstoft J; Pedersen C; Black FT; Lundgren JD; Obel N
    Scand J Infect Dis; 1999; 31(5):489-93. PubMed ID: 10576129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.
    Kuritzkes DR; Bassett RL; Johnson VA; Marschner IC; Eron JJ; Sommadossi JP; Acosta EP; Murphy RL; Fife K; Wood K; Bell D; Martinez A; Pettinelli CB
    AIDS; 2000 Jul; 14(11):1553-61. PubMed ID: 10983642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz.
    Lucas GM; Chaisson RE; Moore RD
    AIDS; 2001 Sep; 15(13):1679-86. PubMed ID: 11546943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).
    Vibhagool A; Cahn P; Schechter M; Smaill F; Soto-Ramirez L; Carosi G; Montroni M; Pharo CE; Jordan JC; Thomas NE; Pearce G
    Curr Med Res Opin; 2004 Jul; 20(7):1103-14. PubMed ID: 15265255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis.
    Rolla VC; da Silva Vieira MA; Pereira Pinto D; Lourenço MC; de Jesus Cda S; Gonçalves Morgado M; Ferreira Filho M; Werneck-Barroso E
    Clin Drug Investig; 2006; 26(8):469-79. PubMed ID: 17163279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.